Price
No data yet.
Social Signal Score
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.59
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
CSFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
95-20.83%Social Signal Score
Mentions (3)
- Newsmarketbeat.com·7h ago·Neutral
Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study Arrowhead Pharmaceuticals NASDAQ: ARWR presented interim Phase I/II data for ARO-MAPT, an investigational small interfering RNA therapy designed to reduce tau protein expression in the central nervous system, alongside initial clinical results for its TRiM CNS delivery platform.
View source ↗ - Newsglobenewswire.com·6d ago·Negative
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests Cerenome secures Florida Blue agreement for CNSide tumor cell and molecular tests, expanding contracted payer access to approximately 164M covered lives.
View source ↗ - Newsglobenewswire.com·8d ago·Positive
Cerenome Launches CNSide® CSF Molecular Profile Tests HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the United States beginning October 12, 2026: CNSide® CSF Molecular Profile – Solid Tumor (DNA & RNA) CNSide® CSF Molecular Profile – Hema…
View source ↗
Congress trades
No disclosed congressional trades in CSF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.